PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för empagliflozin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

25 hits

Bibliografisk träff 2014-12-01

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Riggs MM, Seman LJ, Staab A, MacGregor TR, Gillespie W, Gastonguay MR, Woerle HJ, Macha S.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.12453

Bibliografisk träff 2014-11-01

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.

Macha S, Lang B, Pinnetti S, Broedl UC.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.5414/cp202117

Bibliografisk träff 2014-11-01

Empagliflozin for the treatment of type 2 diabetes.

Jahagirdar V, Barnett AH.

Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2014.966078

Bibliografisk träff 2014-10-01

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.

Scott LJ.

Drugs · review; journal article · DOI 10.1007/s40265-014-0298-1

Bibliografisk träff 2014-10-01

Empagliflozin (Jardiance) for diabetes.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2014-09-30

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ, EMPA-REG BP Investigators.

Diabetes Care · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.2337/dc14-1096

Bibliografisk träff 2014-09-26

Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.

Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, Hart SE, Blanchard K.

Int J Toxicol · research support, non-u.s. gov't; journal article · DOI 10.1177/1091581814551648

Bibliografisk träff 2014-09-05

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Sarashina A, Ueki K, Sasaki T, Tanaka Y, Koiwai K, Sakamoto W, Woerle HJ, Salsali A, Broedl UC, Macha S.

Clin Ther · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.clinthera.2014.08.001

Bibliografisk träff 2014-07-03

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.

Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, Klein T, Mayoux E.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.114.213454

Bibliografisk träff 2014-07-01

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.

Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T.

Diabetes Metab Syndr Obes · research-article; journal article · DOI 10.2147/dmso.s58786

Bibliografisk träff 2014-06-24

Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.

Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC.

Adv Ther · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s12325-014-0126-8

Bibliografisk träff 2014-06-18

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C.

Am J Physiol Renal Physiol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1152/ajprenal.00145.2014

Bibliografisk träff 2014-06-16

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.

Lancet Diabetes Endocrinol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s2213-8587(14)70120-2

Bibliografisk träff 2014-06-14

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, EMPA-REG MDI Trial Investigators.

Diabetes Care · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2337/dc13-3055

Bibliografisk träff 2014-06-11

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Neumiller JJ.

Drugs Context · review-article; review; journal article · DOI 10.7573/dic.212262

Bibliografisk träff 2014-05-28

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.

Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A.

Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/dom.12307

Bibliografisk träff 2014-04-19

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.

Lamos EM, Younk LM, Davis SN.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2014.909407

Bibliografisk träff 2014-04-10

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, EMPA-REG MET Trial Investigators.

Diabetes Care · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2337/dc13-2105

Bibliografisk träff 2014-04-09

Empagliflozin for the treatment of Type 2 diabetes.

Gangadharan Komala M, Mather A.

Expert Rev Clin Pharmacol · review; journal article · DOI 10.1586/17512433.2014.908703

Bibliografisk träff 2014-02-01

Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.

Macha S, Koenen R, Sennewald R, Schöne K, Hummel N, Riedmaier S, Woerle HJ, Salsali A, Broedl UC.

Clin Ther · multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2014.01.003

Bibliografisk träff 2014-01-24

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG RENAL trial investigators.

Lancet Diabetes Endocrinol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s2213-8587(13)70208-0

Bibliografisk träff 2013-11-13

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T.

Am J Physiol Renal Physiol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1152/ajprenal.00520.2013

Bibliografisk träff 2013-08-22

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/dom.12188

Bibliografisk träff 2013-08-19

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC.

Diabetes Obes Metab · clinical trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1111/dom.12182

Bibliografisk träff 2013-08-19

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ.

Diabetes Obes Metab · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1111/dom.12183